Antibiotic combination therapy can select for broad-spectrum multidrug resistance in Pseudomonas aeruginosa

Keyphrases

• Combination Therapy 100%
• Pseudomonas Aeruginosa (P. aeruginosa) 100%
• Antibiotic Combination Therapy 100%
• Multidrug Resistance 100%
• Broad-spectrum Resistance 75%
• Operon 50%
• Drug Exposure 50%
• Resistance Mechanism 50%
• Single Drug 50%
• Resistance mutations 25%
• Antimicrobial Resistance 25%
• Fluoroquinolones 25%
• Antibiotics 25%
• Regulatory Genes 25%
• Ciprofloxacin 25%
• Decreased Susceptibility 25%
• Ceftazidime 25%
• Deregulation 25%
• Drug Combination 25%
• MexCD-OprJ 25%
• Antibiotic Use 25%
• Ciprofloxacin Resistance 25%
• Fitness Testing 25%
• Repressor 25%
• Resistance Phenotypes 25%
• In Vivo Fitness 25%
• Penicillin-binding Proteins 25%
• Efflux Pump Regulators 25%
• Allelic Replacement 25%
• Ceftazidime Resistance 25%
• Major Resistance 25%
• Drug Efflux 25%
• MexR 25%
• Resistance Evolution 25%
• OprM 25%
• Antibiotic Class 25%
• Gene Encoding 25%
• Narrow Spectrum 25%
• Beta-lactams 25%
• NfxB 25%
• Enhanced Fitness 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Therapy 100%
• Pseudomonas aeruginosa 100%
• Antibiotic Agent 100%
• Antimicrobial Agent 100%
• Multidrug Resistance 100%
• Effusion 50%
• Ciprofloxacin 50%
• Ceftazidime 50%
• Quinolone Derivative 25%
• Antibiotics 25%
• Lactam 25%
• Penicillin Binding Protein 25%
• Antibiotic Resistance 25%

Immunology and Microbiology

• Pseudomonas aeruginosa 100%
• Multidrug Resistance 100%
• Antimicrobial Agent 100%
• Operon 66%
• Drug Exposure 66%
• Regulator Gene 33%
• Repressor Gene 33%
• Penicillin Binding Protein 33%
• In Vitro 33%
• Susceptibility 33%
• Antibiotic Resistance 33%